US FDA committee recommends approval of Akcea's Waylivra to treat familial chylomicronemia syndrome

Akcea Therapeutics, Inc, an affiliate of Ionis Pharmaceuticals, Inc., announced that the US Food and Drug Administration's (FDA) Division of Metabolism and Endocrinology Products Advisory Committee voted

More From BioPortfolio on "US FDA committee recommends approval of Akcea's Waylivra to treat familial chylomicronemia syndrome"